Clevidence

Clevidence Clevidence stands for clear evidence.

Our aim is to deliver evidence-based assessments that can be used with confidence by health decision-makers and other stakeholders in healthcare.

Orphan drugs force HTA systems into their hardest trade-off: urgent need vs. limited evidence.In rare diseases, uncertai...
03/06/2026

Orphan drugs force HTA systems into their hardest trade-off: urgent need vs. limited evidence.

In rare diseases, uncertainty is not a “problem to hide”, it’s a feature of the context. Small samples, short follow-up, and imperfect comparators are often unavoidable. But what is avoidable is letting that uncertainty become vague, unstructured, and therefore easy to dismiss.

The most credible dossiers don’t pretend the data is stronger than it is. They do something far more persuasive: they make uncertainty measurable, explainable, and governable. That’s how you build confidence, not by promising certainty, but by demonstrating decision quality and a credible path to learn fast after access.

Strong HTA submissions do not succeed by volume of data. They succeed when the evidence is designed around the decision ...
27/05/2026

Strong HTA submissions do not succeed by volume of data. They succeed when the evidence is designed around the decision context, what must be concluded, against which comparators and for which patients in routine care.

An HTA-ready evidence strategy starts early. It defines the decision, frames the scope (population, comparators, outcomes), and uses systematic synthesis to make uncertainty explicit and actionable.

At Clevidence, we help teams build decision-ready evidence strategies across medicines, devices, and digital health, so submissions are clearer, more relevant and easier to defend.

Start now with Clevidence.

20/05/2026

Reimbursement discussions can be noisy... Multiple stakeholders, competing priorities, and evidence that can be interpreted in different ways.

But a clear strategy brings structure to that complexity. It anticipates the questions that matter, reduces uncertainty and strengthens the rationale for decision-making. That is what turns complexity into a clear, defensible reimbursement case.

Start a conversation with Clevidence and discuss how to improve clarity and confidence in your next reimbursement conversation.

Budget impact and cost-effectiveness are often mentioned together—but they answer fundamentally different questions in p...
13/05/2026

Budget impact and cost-effectiveness are often mentioned together—but they answer fundamentally different questions in payer decision-making.

Budget impact quantifies the expected total spend for a healthcare system over a defined period. Cost-effectiveness assesses whether the health outcomes delivered justify the additional costs versus current care.

When these concepts are conflated, discussions become less precise and decisions become harder to justify. However, when they are used correctly, they provide a clearer basis for reimbursement conditions, implementation planning, and sustainable access. The strongest market access strategies treat them as complementary, not interchangeable.

Looking forward to align both analyses for your product or portfolio? Book a consultation.

Market access is what turns a medicine’s regulatory approval into real-world patient availability. It is the disciplined...
06/05/2026

Market access is what turns a medicine’s regulatory approval into real-world patient availability. It is the disciplined work of demonstrating value, clinically and economically, so healthcare systems can make informed reimbursement and adoption decisions.

In practice, this is where many launches succeed or stall. Authorisation may confirm a product can be used, but market access determines whether it will be used within a funded pathway.

So, understanding the core logic behind market access and why a clear evidence strategy matters from the outset is what determines whether an innovation reaches patients at scale or remains confined to regulatory approval.

In payer decision-making, the technology label matters far less than the logic behind the answer to what changes, what i...
29/04/2026

In payer decision-making, the technology label matters far less than the logic behind the answer to what changes, what it costs and how certain we are.

This is why value discussions should be framed around comparability and confidence. Different evidence pathways can lead to the same decision standard, as long as the reasoning is transparent and the trade-offs are made explicit.

In a constrained system, the payer’s job is to prioritise, funding what delivers the greatest additional value for the resources available. For companies, that means value cannot be assumed, it must be demonstrated in a way that matches how payers decide.

Healthcare decisions are rarely made with perfect information, they’re made under time pressure, scrutiny, and real-worl...
22/04/2026

Healthcare decisions are rarely made with perfect information, they’re made under time pressure, scrutiny, and real-world constraints.

That is when methodology matters most. A systematic approach to evidence isn’t bureaucracy, it’s how we protect decision quality. It helps ensure the conclusions we rely on are built on the whole body of research, assessed consistently, and communicated with transparency about what we know and what we don’t.

That rigour is what turns evidence into decision-ready insight that stakeholders can trust.

16/04/2026

When the evidence is strong, uncertainty doesn’t have to be.

Clevidence helps you build payer-facing confidence, across HTA, market access and value evidence.

Book a call. Let’s turn your evidence into a confident “yes”.

In any industry, every choice has an opportunity cost, often invisible until outcomes (and budgets) are under pressure. ...
13/04/2026

In any industry, every choice has an opportunity cost, often invisible until outcomes (and budgets) are under pressure.
That is why decision-makers are increasingly moving beyond “Does it work?” towards a more demanding question: “Is it the best use of what we have?”

In healthcare, economic evaluation brings structure, transparency and accountability to these choices, helping align clinical value with payer expectations and long-term sustainability.
Because in a system under constant pressure, clarity cannot be a luxury. It is governance.

30/03/2026

And that’s a wrap on DIA Europe 2026.

We’re leaving Rotterdam with renewed momentum and a stronger network of connections and follow-up conversations already in motion.

The energy in Rotterdam set the tone. Sharp discussions, real-world challenges and a shared ambition to raise the standard for evidence-based decisions. Exactly the kind of spirit this industry needs.
Thank you to everyone who visited Clevidence and helped make this event so purposeful.

See you next year, DIA Europe.

Endereço

Avenida Jacques Delors, Edifício Inovação II, 411/421
Porto Salvo
2740-122

Horário de Funcionamento

Segunda-feira 09:00 - 17:30
Terça-feira 09:00 - 17:30
Quarta-feira 09:00 - 17:30
Quinta-feira 09:00 - 17:30
Sexta-feira 09:00 - 17:30

Telefone

+351913852490

Website

Notificações

Seja o primeiro a receber as novidades e deixe-nos enviar-lhe um email quando Clevidence publica notícias e promoções. O seu endereço de email não será utilizado para qualquer outro propósito, e pode cancelar a subscrição a qualquer momento.

Entre Em Contato Com O Negócio

Envie uma mensagem para Clevidence:

Atalhos

Compartilhar

Categoria